Masaoki Ito

Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy

Yoshitsugu Mitani, Naohide Oue, Satoko Matsumura et al. · Oncogene · 2007 · 120 citations

Prognostic Biomarkers, Reg Iv, Medicine +8

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis

Niki Karachaliou, Imane Chaib, Andrés F. Cardona et al. · EBioMedicine · 2018 · 77 citations · Full text

Common Co-activation, Medicine, Pathology +9

Clinicopathologic Features and Response to Therapy of<i>NRG1</i>Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry

Alexander Drilon, M. Duruisseaux, Ji‐Youn Han et al. · Journal of Clinical Oncology · 2021 · 70 citations · Full text

Positive EGFR mutation status is a risk of recurrence in pN0–1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis

Masaoki Ito, Yoshihiro Miyata, Yasuhiro Tsutani et al. · Lung Cancer · 2020 · 65 citations

Oncology, Retrospective Multi-center Analysis, Medicine +10

Outcomes after lobar versus sublobar resection for clinical stage I non−small cell lung cancer in patients with interstitial lung disease

Yasuhiro Tsutani, Takeshi Mimura, Yuichiro Kai et al. · Journal of Thoracic and Cardiovascular Surgery · 2017 · 59 citations · Full text

Clinical Stage, Surgical Oncology, Interventional Pulmonology +10